Baker Bros. Advisors LP Aravive, Inc. Transaction History

Baker Bros. Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.2 - $1.83 $3.91 Million - $5.97 Million	3,261,224 New	3,261,224 $4.3 Million
Q4 2020 Feb 16, 2021	SELL	$4.36 - $6.51 $330,723 - $493,809	-75,854 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.7 - $12.06 $790,544 - $2.03 Million	-168,201 Reduced 68.92%	75,854 $357,000
Q2 2020 Aug 14, 2020	SELL	$5.18 - $14.81 $1.26 Million - $3.59 Million	-242,278 Reduced 49.82%	244,055 $2.84 Million
Q1 2020 May 15, 2020	BUY	$3.5 - $13.77 $185,500 - $729,810	53,000 Added 12.23%	486,333 $2.8 Million
Q4 2019 Feb 14, 2020	SELL	$6.21 - $14.02 $1.43 Million - $3.24 Million	-230,755 Reduced 34.75%	433,333 $5.92 Million
Q3 2019 Nov 14, 2019	BUY	$5.2 - $8.68 $931,533 - $1.55 Million	179,141 Added 36.94%	664,088 $4.98 Million
Q2 2019 Aug 14, 2019	BUY	$5.65 - $7.5 $305,450 - $405,465	54,062 Added 12.55%	484,947 $2.91 Million
Q1 2019 May 15, 2019	BUY	$3.35 - $8.27 $88,778 - $219,163	26,501 Added 6.55%	430,885 $3.03 Million
Q4 2018 Feb 13, 2019	BUY	$3.23 - $8.7 $1.31 Million - $3.52 Million	404,384 New	404,384 $1.42 Million

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.